FindTrial
Sign In

A Prospective Observational Study to Evaluate the dynamic Changes of Serum HMGB1 after Thrombolytic Therapy in Acute Stroke Patients

The Inflammatory Response Mediated by HMGB1-RAGE Regulates the Destruction of BBB and Hemorrhage in Thrombolytic Therapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16010052
Enrollment
Unknown
Registered
2016-11-30
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Case series:thrombolytic therapy

Sponsors

Nanfang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Enrollment criteria included subjects presenting with acute cerebral vascular ischemia met the criteria for thrombolysis.

Exclusion criteria

Exclusion criteria: Those suffering from acute inflammatory illness, cancer, or autoimmune diseases, such as pneumonia, hepatitis, HIV, systemic lupus erythematosus, recently taken anti-inflammatory drugs or glucocorticoid, received other combined therapy, such as embolectomy.

Design outcomes

Primary

MeasureTime frame
the level of serum HMGB1;—

Secondary

MeasureTime frame
NIHSS score;—

Countries

China

Contacts

Public ContactGu Yong

Nanfang Hospital

guyongweb@126.com+86 15521280288

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 23, 2026